MDS is a bone marrow failure disorder
MDS is a blood cancer
Learn More >
Loading Events

« All Events

Outcomes for High-Risk MDS Patients Undergoing Transplant vs Standard Non-Transplant Therapies Webinar

August 7 @ 12:00 pm - 1:30 pm

  • August 7, 2021: Outcomes for High-Risk MDS Patients Undergoing Transplant vs Standard Non-Transplant Therapies @12 pm ET
    Erica D. Warlick, MD, University of Minnesota Medical Center
    This webinar will provide an overview of the role of allogeneic hematopoietic cell transplantation (alloHCT) for high-risk MDS patients. Standard therapies for patients with MDS including hypomethylating agents (HMAs) and a variety of novel agents outside of allogeneic HCT will be discussed.
    Register Now

Details

Date:
August 7
Time:
12:00 pm - 1:30 pm
Review answers to commonly asked questions or get answers to your questions from an MDS expert